Targeting the AKT pathway in glioblastoma
- PMID: 21827416
- DOI: 10.2174/138161211797249224
Targeting the AKT pathway in glioblastoma
Abstract
Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults. The treatment options for patients diagnosed with GBM are limited and the current median survival is 14-16 months following diagnosis. Genetic mutations have been identified that act as drivers of GBM growth and these should be considered as a basis for identifying novel therapeutic strategies. AKT is a downstream serine/threonine kinase in the RTK/PTEN/PI3K pathway and large scale genomic analysis of GBM has demonstrated that this pathway is mutated in the majority of GBMs. This RTK/PTEN/PI3K pathway leads to activated AKT and phospho-AKT levels are elevated in the majority of GBM tumor samples and cell lines, which studies show help glioma cells grow uncontrolled, evade apoptosis, and enhance tumor invasion. AKT represents a nodal point in this pathway which allows for amplification of growth signals, thereby making inhibition of AKT an attractive target for GBM therapy. Many different classes of AKT inhibitors exist, however, few have been tested sufficiently to demonstrate in vivo efficacy. This article will summarize the key components of the Akt pathway with special attention to gliomas, the genetic alterations driving this pathway in gliomas, and the studies evaluating inhibitors of this pathway. Inhibitors of the Akt pathway represent a potential treatment option against GBM and additional research efforts are required to fully explore and develop this possible treatment strategy.
Similar articles
-
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma.Oncotarget. 2016 May 31;7(22):33440-50. doi: 10.18632/oncotarget.7961. Oncotarget. 2016. PMID: 26967052 Free PMC article. Review.
-
Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway.Oncol Rep. 2019 Aug;42(2):605-614. doi: 10.3892/or.2019.7204. Epub 2019 Jun 19. Oncol Rep. 2019. PMID: 31233190 Free PMC article.
-
Inhibition of glycolytic metabolism in glioblastoma cells by Pt3glc combinated with PI3K inhibitor via SIRT3-mediated mitochondrial and PI3K/Akt-MAPK pathway.J Cell Physiol. 2019 May;234(5):5888-5903. doi: 10.1002/jcp.26474. Epub 2018 Dec 19. J Cell Physiol. 2019. PMID: 29336479
-
Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.Mol Cancer. 2017 Jun 7;16(1):100. doi: 10.1186/s12943-017-0670-3. Mol Cancer. 2017. PMID: 28592260 Free PMC article. Review.
-
NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.Cancer Lett. 2015 Oct 10;367(1):58-68. doi: 10.1016/j.canlet.2015.07.007. Epub 2015 Jul 15. Cancer Lett. 2015. PMID: 26188279
Cited by
-
LPA signaling is regulated through the primary cilium: a novel target in glioblastoma.Oncogene. 2018 Mar;37(11):1457-1471. doi: 10.1038/s41388-017-0049-3. Epub 2018 Jan 11. Oncogene. 2018. PMID: 29321663 Free PMC article.
-
Anti-Tumor Functions of Prelatent Antithrombin on Glioblastoma Multiforme Cells.Biomedicines. 2021 May 7;9(5):523. doi: 10.3390/biomedicines9050523. Biomedicines. 2021. PMID: 34067120 Free PMC article.
-
MiR-3116 sensitizes glioma cells to temozolomide by targeting FGFR1 and regulating the FGFR1/PI3K/AKT pathway.J Cell Mol Med. 2020 Apr;24(8):4677-4686. doi: 10.1111/jcmm.15133. Epub 2020 Mar 17. J Cell Mol Med. 2020. PMID: 32181582 Free PMC article.
-
TP3, an antimicrobial peptide, inhibits infiltration and motility of glioblastoma cells via modulating the tumor microenvironment.Cancer Med. 2020 Jun;9(11):3918-3931. doi: 10.1002/cam4.3005. Epub 2020 Apr 7. Cancer Med. 2020. PMID: 32266797 Free PMC article.
-
The Curcumin Analog C-150, Influencing NF-κB, UPR and Akt/Notch Pathways Has Potent Anticancer Activity In Vitro and In Vivo.PLoS One. 2016 Mar 4;11(3):e0149832. doi: 10.1371/journal.pone.0149832. eCollection 2016. PLoS One. 2016. PMID: 26943907 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials